COMPANY SUMMARY BIO Boston 1x1 meeting NOSOPHARM ___________ NAME - PDF document

COMPANY SUMMARY BIO Boston 1x1 meeting NOSOPHARM ___________ NAME OF THE CEO Philippe VILLAIN-GUILLOT MISSION The mission of Nosopharm is to discover and develop novel first-in-class anti- infective agents addressing the treatment of severe and life-threatening multidrug- resistant hospital -acquired infections. TECHNOLOGY Nosopharm has designed and developed a proprietary innovative and unique anti- infective drug discovery platform based on an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus. COMPETITION Competitors with first-in-class antibacterials under development: Bugworks, ADRESS Curza, Forge Therapeutics, Polyphor 21 av Georges Pompidou Competitors with first-in-class antifungals under development: Scynexis, Vical Danica B ALLIANCES/PARTNERSHIPS 69486 Lyon Cedex 03 ________________________ European R&D consortium IMI ND4BB ENABLE (http://nd4bb-enable.eu/) EMAIL University of Illinois at Chicago p.villainguillot@nosopharm.com www.nosopharm.com UPCOMING CATALYSTS MANAGEMENT TEAM CEO: Philippe VILLAIN-GUILLOT IND approval for the first-in-class antibiotic NOSO-502 CSO: Maxime GUALTIERI Qualified Infectious Disease Product designation by the FDA for NOSO-502 Phase 1 clinical trials for NOSO-502 TARGETED Discovery and development of a new class of antibiotics for the treatment of MARKET Pseudomonas aeruginosa infection ___________ Discovery and development of a new class of antifungals for the treatment of Candida infection, especially the multidrug-resistant Candida glabrata and The business model of Nosopharm Candida auris is to feed the antimicrobial pipeline of the Pharma and Biotech companies with novel first-in-class anti-infective agents developed up to Phase 1 clinical trials. NOSO- 502, the first clinical candidate of the new Odilorhadbin antibiotic class, targets the treatment of multidrug-resistant Enterobacteriaceae infections, including carbapenem-resistant Enterobacteriaceae (CRE), a pathogen categorized as an urgent threat by the CDC (Center for Disease Control & Prevention) PRIVATE COMPANY CREATION DATE March 2009

COMPANY SUMMARY BIO Boston 1x1 meeting NOSOPHARM ___________ NAME OF THE CEO Philippe VILLAIN-GUILLOT KEY FIGURES € m 2016 2017 Sales 0 0 EBIT -0,9 -1,5 Net Income -0.4 -0,9 Cash Position 0,5 1,8 SHAREHOLDERS (percentage) ADRESS Funders (Philippe VILLAIN-GUILLOT, Maxime GUALTIERI): 31.7% 21 av Georges Pompidou Venture Capital (Auriga, Kreaxi, Alto Invest): 34.3% Danica B Business angels: 34.0% 69486 Lyon Cedex 03 ________________________ PIPELINE EMAIL p.villainguillot@nosopharm.com Product Lead to IND- www.nosopharm.com Target Pathogen Class Discovery Phase 1 Candidate Candidate enabling MANAGEMENT TEAM Enterobacteriaceae NOSO-502 Odilorhabdin CEO: Philippe VILLAIN-GUILLOT CSO: Maxime GUALTIERI P. aeruginosa NOSO-A4 Madelorhabdin TARGETED Candida spp. NOSO-F2 Candidarhabdin MARKET ___________ The business model of Nosopharm is to feed the antimicrobial pipeline of the Pharma and Biotech companies with novel first-in-class anti-infective agents developed up to Phase 1 clinical trials. NOSO- 502, the first clinical candidate of the new Odilorhadbin antibiotic class, targets the treatment of multidrug-resistant Enterobacteriaceae infections, including carbapenem-resistant Enterobacteriaceae (CRE), a pathogen categorized as an urgent threat by the CDC (Center for Disease Control & Prevention) PRIVATE COMPANY CREATION DATE March 2009